Immunology of murine leishmaniasis

Clinics in Dermatology

Volumn 14, Issue 5, 1996, Pages 451-464

  McSorley, Stephen ^a   Proudfoot, Lorna ^a   O'Donnell, Catherine Agnes ^a   Liew, Foo Yew ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY RESPONSE; CELLULAR IMMUNITY; HELPER CELL; INFECTION RESISTANCE; LEISHMANIASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE SUBPOPULATION;

EID: 0030249845     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0738-081X(96)00037-5     Document Type: Article

References (165)

1. 1. Turk JL, Bryceson ADM. Immunological phenomena in leprosy and related diseases. Adv Immunol 1971;13:209-66.
2. 2. Liew FY, O'Donnell CA. Immunology of Leishmaniasis. Adv Parasitol 1993;32:161-81.
3. 3. Wassom DL, Kelly E. The role of the major histocompatibility complex in resistance to parasite infections. Crit Rev Immunol 1990;10:31-52.
4. 4. Bradley DJ. Regulation of Leishmania populations within the host. II. Genetic control of acute susceptibility of mice to Leishmania donovani infection. Clin Exp Immunol 1977; 30:130-40.
5. 5. Plant JE, Blackwell JM, O'Brien AD, et al. Are the lsh and Ity disease resistant genes at one locus on mouse chromosome 1? Nature 1982;297:570-1.
6. 6. Skamene E, Gros P, Forget A, et al. Genetic regulation of resistance to intracellular pathogens. Nature 1982;297: 506-9.
7. 7. Crocker PR, Blackwell JM, Bradley DJ. Expression of the natural resistance gene Lsh in resident liver macrophages. Infect Immun 1984;43:1033-40.
8. 8. Vidal SM, Malo D, Vogan K, et al. Natural resistance to infection with intracellular parasites: Isolation of a candidate for BCG. Cell 1993;73:469-85.
9. 9. Unkles SE, Hawker KL, Grieve C, et al. CrnA encodes a nitrate transporter in Aspergillus nidulans. Proc Natl Acad Sci USA 1991;88:204-8.
10. 10. Green SJ, Meltzer MS, Hibbs JB Jr, et al. Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism. J Immunol 1990;144:278-83.
11. 11. Liew FY, Millott S, Parkinson C, et al. Macrophage killing of Leishmania parasites in vivo is mediated by nitric oxide from L-arginine. J Immunol 1990;144:4794-7.
12. 12. Liew FY, Cox FEG. Nonspecific defence mechanism: the role of nitric oxide. Immunoparasitol Today 1991; A17-21.
13. 13. Blackwell JM, Freeman JC, Bradley DJ. Influence of H-2 complex on acquired resistance to Leishmania donovani infection in mice. Nature 1980;283:72-4.
14. 14. Blackwell JM, Hale C, Roberts MB, et al. An H-11-linked gene has a parallel effect on Leishmania major and Leishmania donovani infections in mice. Immunogenetics 1985; 21:385-95.
15. 15. DeTolla LJ, Semprevivo LH, Polczuk NC, et al. Single gene control of resistance to visceral leishmaniasis in mice. Immunogenetics 1980;10:353-61.
16. 16. Blackwell JM. Leishmania donovani infection in heterozygous and recombinant H-2 haplotype mice. Immunogenetics 1983;18:101-9.
17. 17. Mock BA, Fortier AH, Potter M. Genetic control of systemic Leishmania major infection: Identification of subline differences for susceptibility to disease. Curr Top Microbiol Immunol 1986;122:115-21.
18. 18. Howard JG, Hale C, Chan-Liew WL. Immunological regulation of cutaneous leishmaniasis. I. Immunogenetic aspects of susceptibility to Leishmania tropica in mice. Parasite Immunol 1980;2:303-14.
19. 19. Roberts M, Mock BA, Blackwell JM. Mapping of genes controlling Leishmania major infection in CXS recombinant inbred mice. Eur J Immunogenet 1993;20:349-62.
20. 20. Reiner SL, Locksley RM. The regulation of immunity to Leishmania major. Annu Rev Immunol 1995;13:151-77.
21. 21. Liew FY. Regulation of cell-mediated immunity in Leishmaniasis. Curr Top Microbiol Immunol 1990;155:54-64.
22. 22. Scott P. The role of TH1 and TH2 cells in experimental cutaneous leishmaniasis. Exp Parasitol 1989;68:369-72.
23. 23. Pearson RD, Stiegbigel RT. Mechanism of lethal effect of human serum upon Leishmania donovani. J Immunol 1980; 125:2195-201.
24. 24. Herman R. Cytophilic and opsonic antibodies in visceral leishmaniasis in mice. Infect Immun 1980;28:585-93.
25. 25. Handman E, Mitchell G. Immunization with Leishmania receptor for macrophages protects mice against cutaneous leishmaniasis. Proc Natl Acad Sci USA 1985;82: 5910-4.
26. 26. Anderson S, David JR, McMahon-Pratt D. In vivo protection against Leishmania mexicana mediated by monoclonal antibodies. J Immunol 1983;131:1616-8.
27. 27. Debons-Guillemin MC, Vouldoukis A, Roseto A, et al. Inhibition in vivo of both infective Leishmania major and L. mexicana amazonensis mediated by a single monoclonal antibody. Trans R Soc Trop Med Hyg 1986;80:258-60.
28. 28. Champsi J, McMahon-Pratt D. Membrane glycoprotein M-2 protects against Leishmania amazonenisis infection. Infect Immun 1988;52:3272-9.
29. 29. Olobo JO, Handman E, Curtis JM. Antibodies to Leishmania tropica promastigotes during infection in mice of various genotypes. Aust J Exp Biol Med Sci 1980;58:595-601.
30. 30. Howard JG, Liew FY, Hale C, et al. Prophylactic immunization against experimental leishmaniasis. II. Further characterization of the protective immunity against fatal L. tropica infection induced by irradiated promastigotes. J Immunol 1984;132:450-5.
31. 31. Hale C, Howard JG. Immunological regulation of experimental cutaneous leishmaniasis. 2. Studies with Biozzi high and low responder lines of mice. Parasite Immunol 1981;3:45-55.
32. 32. Scott P, Natovitz P, Sher A. B lymphocytes are required for the generation of T cells that mediate healing of cutaneous leishmaniasis. J Immunol 1986;137:1017-21.
33. 33. Titus RG, Muller I, Kimsey P, et al. Exacerbation of experimental murine cutaneous leishmaniasis with CD4+ Leishmania major-specific T cell lines or clones which secrete interferon-γ and mediate parasite-specific delayed-type hypersensitivity. Eur J Immunol 1991;21:559-67.
34. 34. Sacks DL, Scott PA, Asofsky R, et al. Cutaneous leishmaniasis in anti-IgM-treated mice: Enhanced resistance due to functional depletion of a B cell-dependent T cell involved in the suppressor pathway. J Immunol 1984; 132:2072-7.
35. 35. Handman E, Ceredig R, Mitchell GF. Murine cutaneous leishmaniasis: Disease patterns in intact and nude mice of various genotypes and examination of some difference between normal and impared macrophages. Aust J Exp Biol Med Sci 1979;57:9-29.
36. 36. Mitchell GF, Curtis JM, Handman E. Cutaneous leishmaniasis in mice: Disease patterns in reconstituted nude mice of several genotypes infected with Leishmania tropica. Aust J Exp Biol Med Sci 1980;58:521-32.
37. 37. Preston PM, Carter RL, Leuchars E. Experimental cutaneous leishmaniasis. III. Effects of thymectomy on the course of infection of CBA mice with Leishmania tropica. Clin Exp Immunol 1972;10:337-57.
38. 38. Preston PM, Dumonde DC. Experimental cutaneous leishmaniasis. V. Protective immunity in subclinical and self-healing infection in the mouse. Clin Exp Immunol 1976;23:126-38.
39. - T cells that do not mediate cutaneous DTH. J Immunol 1984;132:456-61.
40. 40. Moll H, Scollay RG, Mitchell GF. Resistance to cutaneous leishmaniasis in nude mice injected with L3T4+ T cells but not with Lyt2+ T cells. Immunol Cell Biol 1988;66: 57-63.
41. 41. Liew FY, Hale C, Howard JG. Immunologic regulation of experimental cutaneous leishmaniasis. V. Characterization of effector and specific suppressor T cells. J Immunol 1982;128:1917-22.
42. 42. Howard JG, Hale C, Liew FY. Immunological regulation of experimental cutaneous leishmaniasis. IV. Prophylactic effect of sublethal irradiation as a result of abrogation of suppressor T cell generation in mice genetically susceptible to Leishmania tropica. J Exp Med 1981;153:557-68.
43. 43. Titus RG, Ceredig R, Cerottini JC, et al. Therapeutic effect of anti-L3T4 monoclonal antibody GK1.5 on cutaneous leishmaniasis in genetically susceptible BALB/c mice. J Immunol 1985;135:2108-14.
44. 44. Behforouz N, Wenger CD, Mathison BA. Prophylactic treatment of BALB/c mice with cyclosporin A and its analog B-5-49 enhances resistance to Leishmania major. J Immunol 1986;136:3067-75.
45. 45. Liew FY, Dhaliwal JS. Distinctive cellular immunity in genetically susceptible BALB/c mice recovered from Leishmania major infection or after subcutaneous immunization with killed parasites. J Immunol 1987;138:450-6.
46. 46. Howard JG, Nicklin S, Hale C, et al. Prophylactic immunization against experimental leishmaniasis. I. Protection induced in mice genetically vulnerable to fatal Leishmania tropica infection. J Immunol 1982;129:2206-11.
47. 47. Dhaliwal JS, Liew FY, Cox FEG. Specific suppressor T cells for delayed-type hypersensitivity in susceptible mice immunized against cutaneous leishmaniasis. Infect Immun 1985;49:417-23.
48. 48. Howard JG, Hale C, Liew FY. Genetically determined susceptibility to Leishmania tropica infection is expressed by haematopoietic donor cells in mouse radiation chimaeras. Nature 1980;288:161-2.
49. 49. Titus RG, Lima GC, Engers HD, et al. Exacerbation of murine cutaneous leishmaniasis by adoptive transfer of parasite-specific helper T cell population capable of mediating Leishmania major specific delayed type hypersensitivity. J Immunol 1984;133:1594-1600.
50. 50. Titus RG, Marchand M, Boon T, et al. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol 1985;7:545-55.
51. 51. Liew FY, Hale C, Howard JG. Prophylactic immunization against experimental leishmaniasis. IV. Subcutaneous immunization prevents the induction of protective immunity against fatal Leishmania major infection. J Immunol 1985;135:2095-101.
52. 52. Liew FY, Singleton A, Cillari E, et al. Prophylactic immunization against experimental leishmaniasis. V. Mechanism of the anti-protective blocking effect induced by subcutaneous immunization against Leishmania major infection. J Immunol 1985;135:2102-7.
53. 53. Mosmann TR, Cherwinsky H, Bond MW, et al: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348-57.
54. 54. Mosmann TR, Coffman RL. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73.
55. 55. Cher DJ, Mosmann TR. Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by Th1 clones. J Immunol 1987;138:3688-94.
56. 56. Coffman RL, Seymour BWP, Lehman DA, et al. The role of helper T cell products in mouse B cell differentiation and isotype regulation. Immunol Rev 1988;102:5-28.
57. 57. Stevens TL, Bossie A, Sanders VM, et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 1988;334:255-8.
58. 58. Heinzel FP, Sadick MD, Holaday BJ et al. Reciprocal expression of interferon γ or interleukin 4 during the resolution or progression of murine leishmaniasis. J Exp Med 1989;169:59-72.
59. 59. Heinzel FP, Sadick MD, Mutha SS. Production of interferon γ, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc Natl Acad Sci USA 1991; 88:7011-5.
60. 60. Snapper CM, Paul WE. Interferon-γ and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 1987;236:944-7.
61. 61. Scott P, Natovitz P, Coffman RL, et al. Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med 1988;168:1675-84.
62. 62. Holaday BJ, Sadick MD, Wang Z-E, et al. Reconstitution of Leishmania immunity in severe combined immunodeficient mice using Th1-and Th2-like cell lines. J Immunol 1991;147:1653-8.
63. 63. Scott P, Caspar P, Sher A. Protection against Leishmania major in BALB/c mice by adoptive transfer of a T cell clone recognizing a low molecular weight antigen released by promastigotes. J Immunol 1990;144:1075-9.
64. 64. Belosevic M, Finbloom DS, Van Der Meide, et al. Administration of monoclonal anti-IFN-γ antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major. J Immunol 1989;143:266-74.
65. 65. Wang Z-E, Reiner SL, Zheng S, et al. CD4+ Effector cells default to the TH2 pathway in interferon γ-deficient mice infected with Leishmania major. J Exp Med 1994;179:1367-71.
66. 66. Sadick MD, Heinzel FP, Holaday BJ, et al. Cure of murine leishmaniasis with anti-interleukin-4 monoclonal antibody. J Exp Med 1990;171:115-27.
67. 67. Scott P. IFN-γ modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J Immunol 1991;147:3149-55.
68. 68. Tobin JF, Reiner SL, Hatam F, et al. Transfected Leishmania expressing biologically active IFN-γ. J Immunol 1993;150:5059-69.
69. 69. Ben-Sasson SZ, Le Gros G, Conrad DH, et al. IL-4 production by T cells from naive donors. IL-2 is required for IL-4 production. J Immunol 1990;145:1127-36.
70. 70. Le Gros G, Ben-Sasson SZ, Seder R, et al. Generation of interleukin 4 (IL-4) producing cell in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4 producing cells. J Exp Med 1990;172:921-9.
71. 71. Heinzel FP, Rerko RM, Hatam F, et al. IL-2 is necessary for the progression of leishmaniasis in susceptible murine hosts. J Immunol 1993;150:3924-31.
72. 72. Mazingue C, Cottrez-Detoeuf F, Louis J, et al. In vitro and in vivo effects of interleukin 2 on the protozoan parasite leishmania. Eur J Immunol 1989;19:487-91.
73. 73. Chatelain R, Varkila K, Coffman RL. IL-4 induces a Th2 response in Leishmania major-infected mice. J Immunol 1992;148:1182-7.
74. 74. Lezama-Davila CM, Williams DM, Gallagher G, et al. Cytokine control of Leishmania infection in the BALB/c mouse: Enhancement and inhibition of parasite growth by local administration of IL-2 or IL-4 is species and time dependent. Parasite Immunol 1992;14:37-48.
75. 75. Carter KC, Gallagher G, Baillie AJ, et al. The induction of protective immunity to Leishmania major in the BALB/c mouse by interleukin 4 treatment. Eur J Immunol 1989; 19:779-82.
76. 76. Leal LMCC, Moss DW, Kuhn R, et al. Interleukin-4 transgenic mice of resistant background are susceptible to Leishmania major infection. Eur J Immunol 1993;23:566-9.
77. 77. Morris L, Troutt AB, McLeod KS, et al. Interleukin 4 but not gamma interferon production correlates with the severity of murine cutaneous leishmaniasis. Infect Immun 1993;61:3459-65.
78. 78. Coffman RL, Varkila K, Scott P, et al. Role of cytokines in the differentiation of CD4+ T-cell subsets in vivo. Immunol Rev 1991;123:189-207.
79. 79. Gajewski TF, Fitch FW. Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine HTL clones. J Immunol 1988;140:4245-52.
80. 80. Fernandez-Botran R, Sanders VM, Mosmann TR, et al. Lymphokine-mediated regulation of the proliferative response of clones of T helper 1 and T helper 2 cells. J Exp Med 1988;168:543-58.
81. H1 cells. Science 1995;269:245-7.
82. 82. Hsieh C-S, Macatonia SE, O'Garra A, et al. Pathogeninduced Th1 phenotype development in CD4+ αβ-TCR transgenic T cells is macrophage dependent. Int Immunol 1993;5:371-82.
83. 83. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989;170:2081-95.
84. 84. Fiorentino DF, Zlotnik A, Viera P, et al IL-10 acts on the antigen presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991;146:3444-51.
85. 85. Mosmann TR, Moore KW. The role of IL-10 in crossregulation of Th1 and Th2 responses. Immunoparasitol Today 1991;A49-53.
86. 86. Street NE, Schumacher JH, Fong TAT, et al. Heterogeneity of mouse helper T cells. Evidence from bulk cultures and limiting dilution cloning for precursors of Th1 and Th2 cells. J Immunol 1990;144:1629-39.
87. 87. Prystowsky MB, Ely JM, Beller DI, et al. Alloreactive cloned T cell lines. VI. Multiple lymphokine activities secreted by helper and cytolytic cloned T lymphocytes. J Immunol 1982;129:2337-44.
88. 88. Firestein GS, Roeder WD, Laxer JA, et al. A new murine CD4+ T cell subset with an unrestricted cytokine profile. J Immunol 1989;143:518-25.
89. H2 cell antigen receptors in experimental leishmaniasis. Science 1993;259:1457-60.
90. 90. Soares LRB, Sercarz EE, Miller A, et al. Vaccination of the Leishmania major susceptible BALB/c mouse. I. The precise selection of peptide determinant influences CD4+ subset expression. Int Immunol 1994;6:785-94.
91. 91. Skeiky YA, Guderian JA, Benson DR, et al. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J Exp Med 1995;181:1527-37.
92. 92. Mougneau E, Altare F, Wakil AE, et al. Expression cloning of a protective Leishmania antigen. Science 1995;268: 563-6.
93. 93. Rossi-Bergmann B, Muller I, Godinho EB. Th1 and Th2 T-cell subsets are differentially activated by macrophages and B cells in murine leishmaniasis. Infect Immun 1993;61:2266-9.
94. 94. Kuchroo VK, Das MP, Brown JA, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/ Th2 developmental pathways: Application to autoimmune disease therapy. Cell 1995;80:707-18.
95. 95. Kaye PM, Rogers NJ, Curry AJ, et al. Deficient expression of co-stimulatory molecules on Leishmania-infected macrophages. Eur J Immunol 1994;00:2850-4.
96. 96. Reiner SL, Zheng S, Wang Z-E, et al. Leishmania promastigotes evade interleukin 12 (IL-12) induction by macrophages and stimulate a broad range of cytokines from CD4+ T cells during initiation of infection. J Exp Med 1994;179:447-56.
97. 97. Kopf M, Le Gros G, Bachmann M, et al. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993;362:245-8.
98. 98. Yoshimoto T, Paul WE. CD4+, NK1.1+ T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J Exp Med 1994;179:1285-95.
99. 99. Schoenhaut DS, Chua AO, Wolitzky AG, et al. Cloning and expression of murine IL-12. J Immunol 1992;148: 3433-40.
100. 100. Gately MK, Desai BB, Wolitzky AG, et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 1991;147:874-80.
101. 101. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989;170:827-31.
102. H1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993;260:547-9.
103. 103. Heinzel FP. Interleukin 12 and the regulation of CD4+ T cell subset responses during murine leishmaniasis. Parasitol Today 1994;10:190-2.
104. 104. Heinzel FP, Schoenhaut DS, Rerko RM, et al. Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 1993;177:1505-9.
105. 105. Sypek JP, Chung CL, Mayor SEH, et al. Resolution of cutaneous leishmaniasis: Interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med 1993;177:1797-802.
106. -). Immunology 1995; 85:1-7.
107. 107. Romangnani S. Human Th1 and Th2 subsets: Doubt no more. Immunol Today 1991;12;256-7.
108. 108. Yamamura M, Uyemura K, Deans RJ. Defining protective responses to pathogens: Cytokine profiles in leprosy lesions. Science 1991;254:277-9.
109. 109. Kemp M, Hey AS, Kurtzhala JAL, et al. Dichotomy of the human T cell response to Leishmania antigens. I. Th1-like response to Leishmania major promastigote antigens in individuals recovered from cutaneous leishmaniasis. Clin Exp Immunol 1994;96:410-5.
110. 110. Holaday BJ, De Lima Pompeu MM, Evans T, et al. Correlates of Leishmania-specific immunity in the clinical spectrum of infection with Leishmania chagasi. J Infect Dis 1993;167:411-7.
111. 111. Carvalho EM, Barral A, Pedral-Sampaio D, et al. Immunologic markers of clinical evolution in children recently infected with L. donovani chagasi. J Infect Dis 1992;165: 535-40.
112. 112. Zwingenberger K, Harms G, Pedrosa C, et al. Determinants of the immune response in visceral leishmaniasis: Evidence for predominance of endogenous interleukin 4 over interferon-gamma production. Clin Immunol Immunopathol 1990;57:242-9.
113. 113. Kurtzhals JAL, Hey AS, Jardim A, et al. Dichotomy of the human T cell response to Leishmania antigens. II. Absent or Th2-like response to gp63 and Th1-like response to lipophosphoglycan-associated protein in cells from cured visceral leishmaniasis patients. Clin Exp Immunol 1994;96:416-21.
114. 114. Kemp M, Kurtzhals JAL, Bendtzen K, et al. Leishmania donovani-reactive Th1 and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Infect Immun 1993;61:1069-73.
115. 115. Milon G, Titus RG, Cerottini J-C et al. Higher frequency of Leishmania major-specific L3T4+ T cells in susceptible BALB/c as compared with resistant CBA mice. J Immunol 1986;136:1467-71.
116. 116. Titus RG, Milon G, Marchal G, et al. Involvement of specific Lyt-2+ T cells in the immunological control of experimentally induced murine cutaneous leishmaniasis. Eur J Immunol 1987;17:1429-33.
117. 117. Muller I. Role of T cell subsets during the recall of immunologic memory to Leishmania major. Eur J Immunol 1992;22:3063-9.
118. 118. Smith LE, Rodrigues M, Russell DG. The interaction between CD8+ cytotoxic T cells and Leishmania-infected macrophages. J Exp Med 1991;174:499-505.
119. 119. Stefani MMA, Muller I, Louis JA. Leishmania major-specific CD8+ T cells are inducers and targets of nitric oxide produced by parasitized macrophages. Eur J Immunol 1994;24:746-52.
120. 120. Muller I, Kropf P, Etges R, et al. Gamma interferon response in secondary Leishmania major infection: Role of CD8+ T cells. Infect Immun 1993;61:3730-8.
121. 2-microglobulin-deficient mice fail to confirm a primary protective role for CD8 cells on experimental Leishmaniasis. J Immunol 1993; 151:2077-86.
122. 122. O'Brien RL, Happ MP, Dallas A, et al. Recognition of a single hsp-60 epitope by an entire subset of γδ T lymphocytes. Immunol Rev 1991;121:155-75.
123. 123. Modlin RL, Pirmez C, Hofman FM, et al. Lymphocytes bearing antigen-specific γ/δ T-cell receptors accumulate in human infectious disease lesions. Nature 1989;339: 544-6.
124. 124. Russo DM, Armitage RJ, Barral-Netto M, et al. Antigen-reactive γδ T cells in human leishmaniasis. J Immunol 1993;151:3712-8.
125. + cells during experimental infection of mice with Leishmania major. J Immunol 1993;150:550-5.
126. 126. Ferrick DA, Schrenzel MD, Mulvania T, et al. Differential production of interferon-γ and interleukin-4 in response to Th1-and Th2-stimulating pathogens by γδ T cells in vivo. Nature 1995;373:255-7.
127. 127. Raulet DH. The structure, function and molecular genetics of the γδ T cell receptor. Annu Rev Immunol 1989;7: 175-89.
128. 128. Kirkpatrick CE, Farrell JP. Leishmaniasis in beige mice. Infect Immun 1982;38:1208-16.
129. 129. Scharton TM, Scott P. Natural killer cells are a source of interferon γ that drives differentiation of CD4+ T cell subsets and induce early resistance to Leishmania major in mice. J Exp Med 1993;178:567-77.
130. 130. Pearson RD, Wheeler DA, Harrison LH, et al. The immunobiology of Leishmaniasis. Rev Infect Dis 1983;5: 907-26.
131. 131. Aebischer T, Moody SF, Handman E. Persistence of virulent Leishmania major in murine cutaneous Leishmaniasis: A possible hazard for the host. Infect Immun 1993;61: 220-6.
132. 132. Wilson ME. Leishmaniasis. Curr Opin Infect Dis 1993;6: 331-41.
133. 133. Moll H, Flohe S, Rollinghoff M. Dendritic cells in Leishmania major-immune mice harbor persistent parasites and mediate an antigen-specific immune response. Eur J Immunol 1995;25:693-9.
134. 134. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol Rev 1991;43:109-42.
135. 135. Liew FY. The role of nitric oxide in parasitic disease. Am Trop Med Parasitol 1993;87:637-42.
136. 136. Nathan C, Xie Q-W. Regulation of biosynthesis of nitric oxide. J Biol Chem 1994;269:13725-8.
137. 137. Bredt DS, Snyder SH. Nitric oxide: A physiologic messenger molecule. Annu Rev Biochem 1994;63:175-95.
138. 138. Marletta MA. Nitric oxide synthase: Aspects concerning structure and catalysis. Cell 1994;78:927-30.
139. 139. Green SJ, Meltzer MS, Hibbs JB, et al. Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism. J Immunol 1990;144:278-83.
140. 140. Green SJ, Crawford RM, Hockmeyer JT, et al. Leishmania major amastigotes initiate the L-arginine-dependent killing mechanism in IFN-γ-stimulated macrophages by induction of tumor necrosis factor-α. J Immunol 1990;145: 4290-7.
141. 141. Liew FY, Millott S, Parkinson C, et al. Macrophage killing of Leishmania parasites in vivo is mediated by nitric oxide from L-arginine. J Immunol 1990;144:4794-7.
142. 142. Liew FY, Li Y, Millott S. Tumor necrosis factor (TNFα) in leishmaniasis. II. TNF-α-induced macrophage leishmanicidal activity is mediated by nitric oxide from L-arginine. Immunol 1990;71:556-9.
143. 143. Mauel J, Ransign A, Buchmuller-Rouillery Y. Killing of Leishmania parasites in activated murine macrophages is based on an L-arginine-dependent process that produces nitrogen derivatives. J Leukoc Biol 1991;49:73-82.
144. r congenic mouse strains. Infect Immun 1991;59:3935-44.
145. 145. Liew FY, Li Y, Severn A, et al. Resistance to Leishmania major infection correlates with the induction of nitric oxide synthase in murine macrophages. Eur J Immunol 1991;21:3009-14.
146. 146. Blackwell JM, Roach TIA, Atkinson SE, et al. Genetic regulation of macrophage priming/activation: The Lsh gene story. Immunol Lett 1991;30:241-8.
147. 147. Formica S, Roach TIA, Blackwell JM. Interaction with extracellular matrix proteins influences Lsh/Ity/Bcg (candidate Nramp) gene regulation of macrophage priming/activation for tumour necrosis factor-alpha and nitrite release. Immunology 1994;82:42-50.
148. 148. Wei X-Q, Charles IG, Smith A, et al. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 1995;375:408-11.
149. 149. Kamijo R, Harada H, Matsuyama T, et al. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science 1994;263:1612-5.
150. 150. Drapier J-C, Hibbs JB Jr. Murine cytotoxic activated macrophages inhibit aconitase in tumor cells. Inhibition involves the iron-sulphur prosthetic group and is reversible. J Clin Invest 1986;78:790-7.
151. 151. Lepoivre M, Fieschi F, Coves J, et al. Inactivation of ribonucleotide reductase by nitric oxide. Biochem Biophys Res Commun 1991;179:442-8.
152. 152. Hibbs JB Jr, Taintor RR, Vavrin Z, et al. Nitric oxide: A cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 1988;157:87-94.
153. 153. Stuehr DJ, Nathan CF. Nitric oxide: A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 1989;169:1543-5.
154. 154. Beckman JS, Beckman TW, Chen J, et al. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990;87:1620-4.
155. 155. Nacy CA, Fortier AH, Meltzer MS, et al. Macrophage activation to kill Leishmania major: Activation of macrophages for intracellular destruction of amastigotes can be induced by both recombinant interferon-gamma and non-interferon lymphokines. J Immunol 1985;135:3505-11.
156. 156. Murray HW, Rubin BY, Rothermel CD. Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes: Evidence that interferon-gamma is the activating lymphokine. J Clin Invest 1983;72:1506-10.
157. 157. Proudfoot L, O'Donnell CA, Liew FY. Glycoinositolphospholipids of Leishmania major inhibit nitric oxide synthesis and reduce leishmanicidal activity in murine macrophages. Eur J Immunol 1995;25:745-50.
158. 158. Titus RG, Sherry B, Cerami A. Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis. J Exp Med 1989;170:2097-104.
159. 159. Liew FY, Parkinson C, Millot S, et al. Tumor necrosis factor (TNFα) in leishmaniasis. I. TNFα mediates host-protection against cutaneous leishmaniasis. Immunology 1990;69:570-3.
160. 160. Bogdan C, Moll H, Solbach W, et al. Tumor necrosis factor-α in combination with interferon-gamma, but not with interleukin-4 activates murine macrophages for elimination of Leishmania major amastigotes. Eur J Immunol 1990;20:1131-5.
161. 161. Vieira LO, Pfeffer K, Mak TW, et al. Mice lacking the TNF receptor p55 control Leishmania major replication but fail to resolve lesions. FASEB J 1994:A972.
162. 162. Liew FY, Li Y, Severn A, et al. A possible novel pathway of regulation by murine T helper type-2 (Th2) cells of a Th1 cell activity via the modulation of the induction of nitric oxide synthase on macrophages. Eur J Immunol 1991;21:2489-94.
163. 163. Cunha FQ, Moncada S, Liew FY. Interleukin-10 (IL-10) inhibits the induction of nitric oxide synthase by interferon-gamma in murine macrophages. Biochem Biophys Res Commun 1992;182:1155-9.
164. 164. Gazzinelli RT, Oswald IP, James SL et al. IL-10 inhibits parasite killing and nitrogen oxide production by IFN-gamma activated macrophages. J Immunol 1992;148: 1792-6.
165. 3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-gamma. J Immunol 1990;145:940-4.